Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA-based and adenoviral vector-based vaccines against variant pseudotyped viruses were measured. BNT162b2 and mRNA-1273-elicite...

Descripción completa

Detalles Bibliográficos
Autores principales: Tada, Takuya, Zhou, Hao, Samanovic, Marie I., Dcosta, Belinda M., Cornelius, Amber, Herati, Ramin S., Mulligan, Mark J., Landau, Nathaniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957851/
https://www.ncbi.nlm.nih.gov/pubmed/35350781
http://dx.doi.org/10.3389/fimmu.2022.797589
_version_ 1784676820820426752
author Tada, Takuya
Zhou, Hao
Samanovic, Marie I.
Dcosta, Belinda M.
Cornelius, Amber
Herati, Ramin S.
Mulligan, Mark J.
Landau, Nathaniel R.
author_facet Tada, Takuya
Zhou, Hao
Samanovic, Marie I.
Dcosta, Belinda M.
Cornelius, Amber
Herati, Ramin S.
Mulligan, Mark J.
Landau, Nathaniel R.
author_sort Tada, Takuya
collection PubMed
description The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA-based and adenoviral vector-based vaccines against variant pseudotyped viruses were measured. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals had less neutralizing titer (IC(50) <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.COV2.S to increase protection from current and future variants.
format Online
Article
Text
id pubmed-8957851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89578512022-03-28 Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies Tada, Takuya Zhou, Hao Samanovic, Marie I. Dcosta, Belinda M. Cornelius, Amber Herati, Ramin S. Mulligan, Mark J. Landau, Nathaniel R. Front Immunol Immunology The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine effectiveness. Here, neutralizing antibody titers elicited by mRNA-based and adenoviral vector-based vaccines against variant pseudotyped viruses were measured. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals had less neutralizing titer (IC(50) <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest a potential benefit by second immunization following Ad26.COV2.S to increase protection from current and future variants. Frontiers Media S.A. 2022-03-08 /pmc/articles/PMC8957851/ /pubmed/35350781 http://dx.doi.org/10.3389/fimmu.2022.797589 Text en Copyright © 2022 Tada, Zhou, Samanovic, Dcosta, Cornelius, Herati, Mulligan and Landau https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tada, Takuya
Zhou, Hao
Samanovic, Marie I.
Dcosta, Belinda M.
Cornelius, Amber
Herati, Ramin S.
Mulligan, Mark J.
Landau, Nathaniel R.
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
title Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
title_full Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
title_fullStr Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
title_full_unstemmed Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
title_short Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
title_sort neutralization of sars-cov-2 variants by mrna and adenoviral vector vaccine-elicited antibodies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957851/
https://www.ncbi.nlm.nih.gov/pubmed/35350781
http://dx.doi.org/10.3389/fimmu.2022.797589
work_keys_str_mv AT tadatakuya neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies
AT zhouhao neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies
AT samanovicmariei neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies
AT dcostabelindam neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies
AT corneliusamber neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies
AT heratiramins neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies
AT mulliganmarkj neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies
AT landaunathanielr neutralizationofsarscov2variantsbymrnaandadenoviralvectorvaccineelicitedantibodies

Ejemplares similares